Lebanon， NH -- Fragility fractures -- at standing height -- are a significant source of sickness and death among the elderly population in the United States. They are also associated with annual direct costs of over $16 billion. As the U.S. population ages， there is an urgent need In pursuit of this goal， a team of researchers from The Dartmouth Institute for Health Policy and Clinical Practice and the Boston University School of Public Health recently looked at whether there was an opportunity to reduce exposure to prescription drugs associated with fracture risk among one high-risk group -- research has shown that not only are such patients at a significantly increased risk of experiencing a second fracture， but that the risk is greatest in the first six months after the first fracture.英语作文
In the study， published online by JAMA Internal Medicine， the researchers analyzed data from a sample of 168，133 Medicare beneficiaries who experienced a fracture of the hip， shoulder of wrist . The researcher team identified 21 drug classes that have been associated with increased fracture risk. After examining them as a single group， they then subdivided them into three groups: those drugs thought to increase fracture risk by increasing the risk of falls， those that decrease bone density， to measure fills for prescripti Among their findings after analysis:
More than three-quarters of the patients in the study were exposed to at least one non-opiate drug associated with an increased fracture risk in the four months before their fracture.
About 7 percent of patients di so the total proportion exposed to high risk drugs did not change.
" among the group we studied，" said lead author Jeffrey Munson， MD， MSCE， assistant professor at The Dartmouth Institute. "To add to that， of these drugs after the fracture event. So that allows for the strong possibility we may be able to prevent at least some of these secondary fragility fractures through better management of high-risk drugs around the time of the first fracture."